Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0001140361-22-020157
Filing Date
2022-05-23
Accepted
2022-05-23 06:15:40
Documents
1

Document Format Files

Seq Description Document Type Size
1 SC 13D/A brhc10037976_sc13d-a.htm SC 13D/A 47681
  Complete submission text file 0001140361-22-020157.txt   48949
Mailing Address C/O REXAHN PHARMACEUTICALS, INC. 15245 SHADY GROVE ROAD, SUITE 455 ROCKVILLE MD 20850
Business Address
Sullivan Lara (Filed by) CIK: 0001769457 (see all company filings)

Type: SC 13D/A

Mailing Address 35 CAMBRIDGE PARK DRIVE CAMBRIDGE MA 02140
Business Address 35 CAMBRIDGE PARK DRIVE CAMBRIDGE MA 02140 (617) 221-9059
Pyxis Oncology, Inc. (Subject) CIK: 0001782223 (see all company filings)

EIN.: 831160910 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-92951 | Film No.: 22949531
SIC: 2834 Pharmaceutical Preparations